Tori D. Gartmond

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Tori

Last Name

Gartmond

NPI

1629539663

Faculty ID

19630

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

185896

Is Open Scheduling

Off

Calie Santana

https://assets.montefioreeinstein.org/profiles/images/11363-calie-santana.jpg

First Name

Calie

Last Name

Santana

NPI

1932310281

Faculty ID

11363

CMO Specialties

Employment Status

Per Diem

Patient Type

Adult

Department

Languages

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Calie Santana joined the Division of General Internal Medicine in 2008. She received her undergraduate degree in Spanish Literature from Cornell University and her medical degree from Harvard Medical School. After residency at Brigham and Women&rsquo;s Hospital and New York Presbyterian-Cornell, she stayed at Cornell, where she became interested in diabetes quality of care. This experience inspired her research as a Robert Wood Johnson Clinical Scholar at Yale, which focused on studying the influence of healthcare organizational characteristics on quality of care.</p>
<p>During her time at Yale, Dr. Santana practiced at the Fair Haven Community Health Center. At Montefiore, she practices and supervises residents at CHCC. Her primary responsibility is as Associate Director of Quality for the Department of Medicine. From this position, Dr. Santana has developed a quality improvement curriculum for PC/SM residents, and coordinates improvement initiatives in inpatient and outpatient care. Dr. Santana also rigorously evaluates the effectiveness of quality improvement interventions and continues to advance the field of implementation science.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5148

Is Open Scheduling

Off

Marina Konopleva

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/3a462040-725e-11ed-bf6e-5b21ae3cc73b.jpg

First Name

Marina

Last Name

Konopleva

NPI

1518063486

Faculty ID

17308

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal">My laboratory and clinical research are focusing on novel agents in acute myeloid leukemia. The main area of active investigations is attacking apoptotic machinery of leukemia cells by depriving them from key pro-survival inputs by targeting BCL-2, BCL-XL, Mcl-1 by small molecule inhibitors and degraders. We continue studies characterizing mechanisms of resistance to BCL-2 inhibition and identifying novel combinatorial strategies with immune therapies and signaling inhibitors. My lab is interested in studying the biology and therapeutic targeting of leukemia-initiating cells, with novel multi-targeted bispecific T- or NK-engagers, antibody-drug conjugates and CART cells. We further aim at identifying key targets in maintenance and eradication of minimal residual disease (MRD) in acute myeloid leukemia (AML). We have studied metabolic states in AML and T-ALL and utilized novel metabolic inhibitors to selectively deprive tumor metabolism, such as glutaminase, OxPhos and fatty acid metabolic inhibitors. Finally, we are interested in understanding the biology and targeting of an aggressive hematologic malignancy Blastic Plasmacytoid Dendritic ell neoplasm (BPDCN), through targeting BCL-2, CD123 and novel cell surface targets with small molecules, antibodies and CART cells. Most robust pre-clinical discoveries have translated into clinical trials, such as venetoclax, metabolic inhibitors and immune modulators.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Myelodysplastic Syndrome (MDS)&nbsp;<br />

Elsevier Profile

Selected Publications

<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, D&ouml;hner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, M&uuml;schen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG (co-corresponding last author). Selective BCL-2 Inhibition by ABT-199 Causes On Target Cell Death in Acute Myeloid Leukemia. Cancer Discov 4(3):362-75, 3/2014. e-Pub 12/2013. PMCID: PMC3975047.</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, Ganesan S, Pan R, Konoplev SN, Sweeney SR, Ryan JA, Jitkova Y, Dunner K, Grosskurth SE, Vijay P, Ghosh S, Lu C, Ma W, Kurtz S, Ruvolo VR, Ma H, Weng CC, Ramage CL, Baran N, Shi C, Cai T, Davis RE, Battula VL, Mi Y, Wang J, DiNardo CD, Andreeff M, Tyner JW, Schimmer A, Letai A, Padua RA, Bueso-Ramos CE, Tiziani S, Leverson J, Popovic R, Konopleva M. Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther 7(1):51, 2/2022. e-Pub 2/2022. PMID: 35185150.</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">&nbsp;</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">DiNardo CD, Konopleva MY. A venetoclax bench-to-bedside story. Nat Cancer 2(1):3-5, 1/2021. PMID: 35121895.</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">&nbsp;</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">Baran N, Lodi A, Dhungana Y,&nbsp; Herbrich S,&nbsp; Collins M, Sweeney S,&nbsp; Pandey R, Skwarska A,&nbsp; Patel S,&nbsp; Tremblay M,&nbsp; Kuruvilla VM,&nbsp; Cavazos A,&nbsp; Kaplan&nbsp; M,&nbsp; Warmoes MO,&nbsp; Veiga DT,&nbsp; Furudate K,&nbsp; Rojas-Sutterin S, Haman A,&nbsp; Gareau Y,&nbsp; Marinier A, Ma H,&nbsp; Harutyunyan K,&nbsp; Daher M,&nbsp; Garcia LM,&nbsp; Al-Atrash G,&nbsp; Piya S, Ruvolo V, Yang W,&nbsp; Shanmugavelandy SS,&nbsp; Feng N,&nbsp; Gay J,&nbsp; Du D,&nbsp; Yang JJ,&nbsp; Hoff FW,&nbsp; Kaminski M,&nbsp; Tomczak K, Davis&nbsp; RE, Herranz D,&nbsp; Ferrando A,&nbsp; Jabbour EJ, Di Francesco ME,&nbsp; Teachey DT,&nbsp; Horton TM,&nbsp; Kornblau S, Rezvani K, Sauvageau G,&nbsp; Gagea M, Andreeff M, Takahashi K,&nbsp; Marszalek JR,&nbsp; Lorenzi PL, Yu J, Tiziani S, Hoang T, Konopleva M. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat Commun. 13(1):2801, 5/2022. PMID:35589701.</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">&nbsp;</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">Cai T, Gouble A, Black KL, Skwarska A, Naqvi AS, Taylor D, Zhao M, Yuan Q, Sugita M, Zhang Q, Galetto R, Filipe S, Cavazos A, Han L, Kuruvilla V, Ma H, Weng C, Liu CG, Liu X, Konoplev S, Gu J, Tang G, Su X, Al-Atrash G, Ciurea S, Neelapu SS, Lane AA, Kantarjian H, Guzman ML, Pemmaraju N, Smith J, Thomas-Tikhonenko A, Konopleva M. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nat Commun 13(1):2228, 4/2022. PMCID: PMC9051102.</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">&nbsp;</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med 380(17):1628-1637, 4/2019. PMID: 31018069.</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">&nbsp;</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">Herbrich S, Baran N, Cai T, Weng C, Aitken MJL, Post SM, Henderson J, Shi C, Richard-Carpentier G, Sauvageau G, Baggerly K, Al-Atrash G, Davis RE, Daver N, Zha D, Konopleva M. Overexpression of CD200 is a Stem Cell-Specific Mechanism of Immune Evasion in AML. J Immunother Cancer 9(7):e002968, 7/2021. PMID: 34326171.</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">&nbsp;</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. (2023). Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials. Nat Med. 29(1), 115-126. PMID: 36658425</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">&nbsp;</p>
<p class="MsoNormal" style="margin-bottom: 0in; line-height: normal;">Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M. (2023). Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica 2023 Apr 20 [<em>online ahead of print</em>]. PMID: 37078252</p>

EMR ID

177440

Biography

<p>Marina Konopleva, MD, Phd, is Professor, Oncology, Professor, Molecular Pharmacology, Director, Leukemia Program and Co-Director, Blood Cancer Institute, at Montefiore Einstein. Her clinic focus centers on treating patients with hematologic malignancies, with an emphasis on acute myeloid and acute lymphoblastic leukemia. She has additional expertise in treating patients with high-risk myelodysplastic syndrome and chronic myeloid leukemia.</p><p>After obtaining her Doctor of Medicine in 1990 from First Pavlov Medical Institute in St. Petersburg, Russia, Dr. Konopleva completed her postgraduate training in internal medicine at I.P. Pavlov State Medical Institute in 1993. In 1998 she obtained her PhD in experimental hematology from the Federal Institute of Hematology and Blood Transfusion as well as her postdoctoral fellowship in Molecular Hematology with The University of Texas MD Anderson Cancer Center.</p><p>Dr. Konopleva conducts laboratory research focusing on approaches activating cell death, metabolic inhibitors and immune-oncology in AML. Her key contributions include the identification of dependency of AML cells on the anti-apoptotic protein BCL-2 and the FDA approval of the BCL-2 inhibitor venetoclax in combination with low-intensity chemotherapy in elderly patients unfit for standard chemotherapy. This therapy provides both low toxicity for elderly patients with AML and documented survival benefit. Dr. Konopleva&rsquo;s ground-breaking research greatly benefited leukemia research, clinical research and the lives of patients. She is a scholar of the Leukemia and Lymphoma Society and her research is funded by the NIH, Department of Defense and various private foundations. Her work has been published in numerous peer-reviewed journals and she has presented both nationally and internationally.</p><p>Dr. Konopleva is board certified by the Russian Board of Hematology, the American Board of Internal Medicine and the American Board of Internal Medicine - Hematology. She is a member of numerous professional societies including the American Society of Hematology, the American Association of Cancer Research, the American Society of Clinical Oncology, the American Society for Clinical Investigation and the Society of Hematologic Oncology.</p><p>Dr. Konopleva has won many awards for her work, such as the R. Lee Clark Prize - Basic/Translational Science and the Students' Faculty Choice Award from MD Anderson Cancer Center in 2019, the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research from MD Anderson Cancer Center in 2020 and the Mentor of the Year award from the Division of Cancer Medicine, MD Anderson Cancer Center in 2022.</p>

Is Open Scheduling

Off

William S. Fuller

https://assets.montefioreeinstein.org/profiles/images/william-fuller.jpg

First Name

William

Last Name

Fuller

NPI

1952721490

Faculty ID

19410

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

11155

Is Open Scheduling

Off

Mary C. Masters

https://assets.montefioreeinstein.org/profiles/images/Masters_Mary_MD_2x.jpg

First Name

Mary

Last Name

Masters

NPI

1811300734

Faculty ID

19463

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

204514

Is Open Scheduling

Off

Nan Gao

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Nan

Last Name

Gao

NPI

1568038024

Faculty ID

19551

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

203749

Is Open Scheduling

Off

Blake A. Bauer

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Blake

Last Name

Bauer

NPI

1558943456

Faculty ID

19471

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

202762

Is Open Scheduling

Off

Jennifer Ognibene

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Jennifer

Last Name

Ognibene

NPI

1437738366

Faculty ID

15028

CMO Specialties

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

202433

Is Open Scheduling

On

August Lindmark

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

August

Last Name

Lindmark

NPI

1578128195

Faculty ID

19450

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Male

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

201615

Is Open Scheduling

On

Tonusri Nag

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Tonusri

Last Name

Nag

NPI

1235587551

Faculty ID

18334

CMO Specialties

Employment Status

Voluntary

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

1875

Is Open Scheduling

Off